• Odi Pharma will hold its annual general meeting in Stockholm on December 4, 2026.
• Shareholders will vote on a proposal to pay no dividend for fiscal 2025/2026.
• Proposals include reelecting all five board members, retaining Volker Wiederrich as chairman, and reappointing Öhrlings PriceWaterhouseCoopers as auditor.
• Proposed board fees are SEK 1 million for Malcolm Allan, SEK 150,000 for Gösta Lidén and SEK 100,000 for each remaining director.
• The agenda also includes adoption of the financial statements and discharge from liability for board members and the managing director.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odi Pharma AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202611041245BITN____UKPR__EN_20261104-BIT-4903-0) on November 04, 2026, and is solely responsible for the information contained therein.